Overview
Hepcidin is a 25–amino acid peptide hormone primarily synthesized and secreted by hepatocytes into the circulation. It is widely referred to as the master regulator of iron homeostasis due to its central role in controlling systemic iron balance. Hepcidin is encoded by the HAMP gene and functions not only as an iron-regulatory hormone but also as a type II acute-phase reactant and an antimicrobial peptide.
Hepcidin regulates iron metabolism by inhibiting iron absorption from the proximal small intestine and blocking iron release from reticuloendothelial macrophages. Its synthesis is strongly influenced by inflammatory cytokines, particularly interleukin-6 (IL-6), linking iron metabolism to inflammation and infection. Because of its regulatory role, abnormal hepcidin levels are implicated in iron deficiency, iron overload syndromes, and anemia of chronic disease. HEPCIDIN
Structure and Functional Significance
Hepcidin is a small peptide with its major biologically active form consisting of 25 amino acids. The molecule contains eight cysteine residues that form four disulfide bonds, giving it a compact bent or hairpin-like structure.
An unusual disulfide bond between adjacent cysteine residues is located at the hairpin turn and plays a critical role in its biological activity. This unique structure allows hepcidin to interact effectively with ferroportin, the iron export channel on enterocytes and macrophages. Functionally, hepcidin is essential for maintaining iron homeostasis and also exhibits antimicrobial activity as part of the innate immune response.
Regulation of Hepcidin Expression
Hepcidin synthesis is tightly regulated by several physiological and pathological factors. Increased body iron stores strongly stimulate hepcidin production to prevent excess iron absorption.
Inflammation is a major inducer of hepcidin expression, primarily mediated through IL-6 and IL-1 signaling pathways. In contrast, hepcidin levels are suppressed in iron deficiency, hypoxic conditions, and states of increased erythropoiesis where iron demand is high.
Vitamin D has a modulatory effect on hepcidin expression and may contribute to iron regulation. This dynamic regulation allows the body to balance iron availability according to metabolic needs and immune status.
Symptoms
Hepcidin itself does not cause direct symptoms. Clinical manifestations arise due to altered iron availability resulting from abnormal hepcidin levels.
Low hepcidin levels lead to excessive iron absorption and iron overload, which may present with fatigue, joint pain, liver dysfunction, skin pigmentation, and endocrine abnormalities. Elevated hepcidin levels restrict iron availability and contribute to anemia, leading to symptoms such as weakness, pallor, reduced exercise tolerance, and fatigue.
Causes
Low hepcidin levels are observed in hereditary hemochromatosis caused by mutations in genes such as HFE, HJV, HAMP, and TFR2. Iron deficiency anemia, increased iron demand, chronic blood loss, hypoxia, and conditions with high erythropoietic drive also suppress hepcidin synthesis.
High hepcidin levels are associated with chronic inflammatory conditions, infections, autoimmune diseases, and cytokine-mediated stimulation. Chronic kidney disease, malignancies, iron overload due to transfusions, excessive iron supplementation, and liver disorders such as fatty liver disease and hepatitis also lead to elevated hepcidin levels.
Risk Factors
Risk factors for abnormal hepcidin levels include chronic inflammatory diseases, autoimmune disorders, chronic infections, kidney disease, and malignancies. Patients with transfusion-dependent anemias or excessive iron supplementation are at risk of iron overload and altered hepcidin regulation.
Genetic mutations affecting iron metabolism, hypoxic conditions, metabolic syndrome, obesity, aging, and hormonal influences such as testosterone also impact hepcidin expression. Individuals with ineffective erythropoiesis, such as β-thalassemia, are particularly prone to hepcidin suppression.
Prevention
There are no direct preventive measures for abnormal hepcidin levels, as they reflect underlying disease processes rather than being primary disorders. Prevention focuses on early identification and management of iron imbalance and associated conditions.
Appropriate evaluation of iron status, treatment of chronic inflammatory states, and careful monitoring of iron therapy help reduce complications related to abnormal hepcidin regulation. Understanding hepcidin levels aids in tailoring iron supplementation and avoiding iron overload or functional iron deficiency.
Clinical Importance and Interpretation
Hepcidin has significant clinical relevance in differentiating iron deficiency anemia from anemia of chronic disease. Elevated hepcidin levels are characteristic of anemia of inflammation, where iron is sequestered despite adequate body stores.
Low hepcidin levels are linked to iron overload syndromes such as hereditary and juvenile hemochromatosis. Hepcidin is also emerging as a therapeutic target in iron-related disorders and anemia management.
It serves as a biomarker in chronic kidney disease, inflammatory disorders, and certain malignancies. Hepcidin testing supports diagnosis, guides iron therapy, and enhances understanding of iron dysregulation in complex disease states.
Methods of Estimation and Sample Collection
Hepcidin can be measured using mass spectrophotometry and immunoassay-based techniques. For testing, patients are instructed to observe overnight fasting.
A 3.0 mL blood sample is collected in a plain red-capped tube, and a 5.0 mL urine sample may also be collected. Results should always be interpreted in correlation with clinical findings and other iron parameters.
